EXPLANATION

Heparin-induced thrombocytopenia (HIT) is an immune-mediated, prothrombotic disorder caused by IgG antibodies directed against platelet factor 4 (PF4)–heparin complexes, which lead to platelet activation, thrombin generation, thrombosis and thrombocytopenia. Diagnosis integrates clinical probability (commonly the 4T score) with laboratory testing. Immunoassays such as PF4 ELISA are highly sensitive but nonspecific, often detecting clinically irrelevant antibodies. Functional assays such as the serotonin release assay (SRA) confirm platelet-activating antibodies and indicate clinically significant HIT. Discordance between assay types is common; however, a positive functional assay reflects ongoing pathogenic immune activity and high thrombotic risk.¹

Management strategies for anticoagulation in patients with HIT undergoing CPB depends in part on the clinical phase of HIT, which reflects the presence and activity of circulating antibodies. In acute HIT and subacute HIT A, platelet-activating antibodies remain detectable by functional assays, and re-exposure to heparin carries a high risk of thrombosis. In contrast, in subacute HIT B or remote HIT, functional assays may become negative despite persistent ELISA positivity, and heparin re-exposure may be safer.² This distinction is critical in determining whether heparin can be used intraoperatively or whether alternative strategies are required.

Several strategies have been described to manage anticoagulation in this setting, though high-quality comparative data are limited. Direct thrombin inhibitors (DTIs) such as bivalirudin and argatroban have been used for CPB to avoid heparin exposure. Previous consensus guidelines have recommended bivalirudin as the anticoagulant of choice over heparin when urgent cardiac surgery with CPB is required.³ However, DTIs are associated with important limitations, including lack of a reversal agent, increased bleeding risk, and potential for circuit thrombosis in areas of low flow within the extracorporeal circuit.² These issues are magnified in critically ill patients with multiorgan dysfunction, such as hepatic and renal impairment, which may prolong drug clearance and further complicate anticoagulation management.

Alternative strategies aim to permit the use of heparin by mitigating HIT antibody activity. One example of this includes the use of TPE and IVIG. Therapeutic plasma exchange (TPE) reduces circulating anti-PF4/heparin antibody titers through removal of pathogenic IgG, often achieving a rapid but transient decrease in antibody burden. Intravenous immunoglobulin (IVIG) complements this by inhibiting Fcγ receptor–mediated platelet activation, thereby functionally blocking residual HIT antibodies that may persist despite TPE.⁴ In practice, TPE is typically performed in the perioperative period, sometimes in multiple sessions depending on antibody levels and urgency, followed by IVIG administration to stabilize the immunologic milieu. This combined approach not only reduces antibody titers but also attenuates platelet activation, enabling safer intraoperative heparin use. The effect, however, may be transient, and antibody rebound has been described, necessitating careful timing relative to surgery and close perioperative monitoring.⁴

Other options used to maintain heparin as the anticoagulant for CPB include the concominant use of antiplatelet agents such as prostacyclin receptor agonists (e.g. iloprost), GP IIb/IIIa antagonists (e.g. tirofiban), and P2Y12 receptor antagonists (e.g. cangrelor), with the goal to prevent HIT related platelet activation and aggregation.² Recent systematic review data suggest that adjunctive strategies such as TPE or antiplatelet agents can reduce thrombotic complications when heparin is required for CPB in HIT patients.⁵ Ultimately, the optimal strategy to mitigate the risks of heparin administration in patients with active HIT requiring CPB is not definitively established, and current approaches are based on limited comparative data and institutional experience.

In this case, argatroban alone (Choice A) is less ideal due to increased thrombotic risk on CPB and high reported rate of intraoperative bleeding.² Switching back to unfractionated heparin without antibody mitigation (Choice B) is contraindicated in active HIT with a positive functional assay, as it directly re-exposes the patient to the inciting antigen and risks acute, potentially fatal thrombosis.

REFERENCES

1. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489

2. Revelly E, Scala E, Rosner L, et al. How to Solve the Conundrum of Heparin-Induced Thrombocytopenia during Cardiopulmonary Bypass. J Clin Med. 2023;12(3):786. Published 2023 Jan 18. doi:10.3390/jcm12030786

3. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S-e530S. doi:10.1378/chest.11-2303

4. Grazioli A, Splinter NP, Plazak ME, et al. Cardiac surgery in acute heparin-induced thrombocytopenia managed with therapeutic plasma exchange and intravenous immunoglobulin. Res Pract Thromb Haemost. 2023;7(2):100089. Published 2023 Feb 23. doi:10.1016/j.rpth.2023.100089

5. Del Vecchio A, Pham LP, McNeil J, et al. Efficacy of Therapeutic Plasma Exchange or Cangrelor as an Adjunctive Strategy to Facilitate Cardiopulmonary Bypass in Patients with Heparin-Induced Thrombocytopenia: A Systematic Review and Meta-Analysis. J Cardiothorac Vasc Anesth. 2024;38(12):2915-2924. doi:10.1053/j.jvca.2024.09.006